Reuters logo
8 months ago
BRIEF-Sumitomo Dainippon Pharma unit signs license contract for three approved treatment options for people with COPD in US
December 22, 2016 / 2:40 AM / 8 months ago

BRIEF-Sumitomo Dainippon Pharma unit signs license contract for three approved treatment options for people with COPD in US

Dec 22 (Reuters) - Sumitomo Dainippon Pharma Co Ltd :

* Says the U.S.-based unit Sunovion Pharmaceuticals Inc. has entered into an exclusive license agreement with Novartis for the U.S. commercialization rights to three approved medicines, which are indicated for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD)

Source text in Japanese:goo.gl/UbBddR

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below